Optimal qMSP cutoff value for MGMT promoter methylation in glioblastoma and its validation for clinical significance
The identified qMSP cut-off value (0.242) based on the procedure described in this study provides a robust prognostic stratification tool for GBM patients. High MGMT methylation correlates with improved survival, supporting its integration into clinical decision-making. Further multi-center validation studies are warranted to establish standardized MGMT assessment methodologies.
Authors
- Ayça Erşen Danyeli (ORCID: https://orcid.org/0000-0001-8015-9916)
- Mehmet Arda İnan (ORCID: https://orcid.org/0000-0002-6179-2828)
- Sibel Erdamar
- Ece Uysal (ORCID: https://orcid.org/0000-0002-2355-8395)
- M. Necmettin Pamir (ORCID: https://orcid.org/0000-0002-5958-8625)
- Koray Özduman (ORCID: https://orcid.org/0000-0002-3543-0401)
- Guzin Gokay (ORCID: https://orcid.org/0000-0001-6647-5920)
- Fuat Kaan Aras
- Turna Demirci
- Zeynep Hüseyinoğlu
Institutions
- Istanbul Aydın University (TR)
- Heidelberg University (DE)
- Acıbadem University (TR)
- Turkish Society of Hematology (TR)
- Altınbaş University (TR)
- Istanbul Medeniyet University (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1186/s12885-025-15225-2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00